Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Mar
04
Today In Oncology
Dietary Influence on Leukemia and Lymphoma Progression
Is Advanced Stage Follicular Lymphoma Curable?
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer
AI Model May Predict Cancer Risk in Patients With Colitis-Associated Low-Grade Dysplasia
Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo